Advent of imidazo[1,2-a]pyridine-3-carboxamides with potent multi- and extended drug resistant antituberculosis activity

ACS Medicinal Chemistry Letters

Volumn 2, Issue 6, 2011, Pages 466-470

  Moraski, Garrett C ^a   Markley, Lowell D ^a   Hipskind, Philip A ^b   Boshoff, Helena ^c   Cho, Sanghyun ^d   Franzblau, Scott G ^d   Miller, Marvin J ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antituberculosis; imidazo 1,2 a pyridine 3 carboxamides; MDR TB; XDR TB

Indexed keywords

2,6 DIMETHYLIMIDAZO[1,2 A]PYRIMIDINE 3 CARBOXAMIDE; 2,7 DIMETHYLIMIDAZO[1,2 A]PYRIDINE 3 CARBOXAMIDE; IMIDAZO[1,2 A]PYRIDINE 3 CARBOXAMIDE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; CONCENTRATION RESPONSE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM KANSASII; MYCOBACTERIUM MARINUM; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

EID: 79959225741     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200036r     Document Type: Article

References (23)

1. Global tuberculosis control: Surveillance, planning, financing: WHO report 2008. WHO/HTM/TB/2008.
2. Sacchettini, J. C.; Rubin, E. J.; Freundlich, J. S. Drugs versus bugs: In pursuit of the persistent predator Mycobacterium tuberculosis Nat. Rev. Microbiol. 2008, 6, 41-52 (Pubitemid 350286219)
3. Migliori, G. B.; De Iaco, G.; Besozzi, G.; Centis, R.; Cirillo, D. M. First tuberculosis cases in Italy resistant to all tested drugs Eurosurveillance 2007, 12, 3194
4. Maher, D.; Blanc, L.; Raviglione, M. WHO policies for tuberculosis control Lancet 2004, 363, 1911-1911
5. Pratt, R.; Robison, V.; Navin, T.; Bloss, E. Centers for Disease Control and Prevention. Trends in Tuberculosis-United States MMWR 2009, 58, 249-253
6. Anaflous, A.; Benchat, N.; Mimouni, S.; Abouricha, S.; Ben-Hadda, T.; El-Bali, A.; Hacht, B. Armed Imidazo [1,2- a ] Pyrimidines (Pyridines): Evaluation of Antibacterial Activity Lett. Drug Des. Discovery 2004, 1, 35-44
7. Kasimogullari, B. O.; Cesur, Z. Fused Heterocycles: Synthesis of Some New Imidazo[1,2- a ]-pyridine Derivatives Molecules 2004, 9, 894-901 (Pubitemid 40132242)
8. Odell, L. R.; Nilsson, M. T.; Gising, J.; Lagerlund, O.; Muthas, D.; Nordqvist, A.; Karlen, A.; Larhed, M. Functionalized 3-amino-imidazo[1,2- a ]pyridines: A novel class of Mycobacterium tuberculosis glutamine synthetase inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 4790-4793
9. Lombardino, J. G. Preparation and New Reactions of Imidazo[1,2- a ]pyridines J. Org. Chem. 1965, 30, 2403-2407
10. Moraski, G. C.; Chang, M.; Villegas-Estrada, A.; Franzblau, S.; Möllmann, U.; Miller, M. J. Structure-Activity Relationship of New Antituberculosis Agents Derived from Oxazoline and Oxazole Benzyl Esters Eur. J. Med. Chem. 2010, 45, 1703-1716
11. Moraski, G. C.; Franzblau, S. G.; Miller, M. J. Utilization of the Suzuki Coupling to Enhance the Antituberculosis Activity of Aryl Oxazoles Heterocycles 2009, 80, 977-988
12. Katritzky, A. R.; Xu, Y. -J.; Tu, H. Regiospecific Synthesis of 3-Substituted Imidazo[1,2- a ]pyridines, Imidazo[1,2- a ]pyrimidines, and Imidazo[1,2- c ]pyrimidine J. Org. Chem. 2003, 68, 4935-4937 (Pubitemid 36682723)
13. Topliss, J. G. Utilization of operational schemes for analog synthesis in drug design J. Med. Chem. 1972, 15, 1006-1011
14. Collins, L.; Franzblau, S. G. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium Antimicrob. Agents Chemother. 1997, 41, 1004-1009 (Pubitemid 27194176)
15. De Voss, J. J.; Rutter, K.; Schroeder, B. G.; Su, H.; Zhu, Y.; Barry, C. E. The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 1252-1257 (Pubitemid 30080845)
16. Cho, S. H.; Warit, S.; Wan, B.; Hwang, C. H.; Pauli, G. F.; Franzblau, S. G. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis Antimicrob. Agents Chemother. 2007, 51, 1380-1385 (Pubitemid 46586820)
17. Falzari, K.; Zhou, Z.; Pan, D.; Liu, H.; Hongmanee, P.; Franzblau, S. G. In Vitro and In Vivo Activities of Macrolide Derivatives against Mycobacterium tuberculosis Antimicrob. Agents Chemother. 2005, 49, 1447-1454 (Pubitemid 40463375)
18. Pethe, K.; Sequeira, P. C.; Agarwalla, S.; Rhee, K.; Kuhen, K.; Phong, W. Y.; Patel, V.; Beer, D.; Walker, J. R.; Duraiswamy, J.; Jiricek, J.; Keller, T. H.; Chatterjee, A.; Tan, M. P.; Ujjini, M.; Roa, S. P. S.; Camacho, L.; Bifani, P.; Mak, P. A.; Ma, I.; Barnes, S. W. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy Nature Commun. 2010, 57, 1-8
19. Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N; Kreiswirth, B. N.; Barry, C. E.; Baker, W. R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis Nature 2000, 405, 962-966 (Pubitemid 30435054)
20. Jeon, C. Y.; Hwang, S. H.; Min, J. H.; Prevots, D. R.; Goldfeder, L. C.; Lee, H.; Eum, S. Y.; Jeon, D. S.; Kang, H. S.; Kim, J. H.; Kim, B. J.; Kim, D. Y.; Holland, S. M.; Park, S. K.; Cho, S. N.; Barry, C. E., 3rd; Via, L. E. Extensively drug-resistant tuberculosis in South Korea: Risk factors and treatment outcomes among patients at a tertiary referral hospital Clin. Infect. Dis. 2008, 46, 42-49 (Pubitemid 351263558)
21. Kana, B. D.; Weinstein, E. A.; Avarbock, D.; Dawes, S. S.; Rubin, H.; Mizrahi, V. Characterization of the cydAB-encoded cytochrome bd oxidase from Mycobacterium smegmatis J. Bacteriol. 2001, 24, 7076-86 (Pubitemid 33121840)
22. Boshoff, H. I.; Myers, T. G.; Copp, B. R.; McNeil, M. R.; Wilson, M. A.; Barry, C. E., 3rd The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action J. Biol. Chem. 2004, 38, 40174-40184 (Pubitemid 39258293)
23. Marrero, J.; Rhee, K. Y.; Schnappinger, D.; Pethe, K.; Ehrt, S. Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 9819-24